This division is responsible for research into medicinal uses of cannabis, including current research into the benefits for those with auto-immune diseases. Innovative pharmaceutical products are developed by our strategic partners for distribution in Australia and targeted global markets. 

The medicinal cannabis market is still in its infancy globally with strict legislation worldwide.  Operating in a complex regulatory environment, Cann Global has positioned the business well to adapt in order to leverage the significant opportunities presented by regulatory changes in the industry.

Our team led by Mr Andrew Kavasilas, has been researching the benefits of Medical Cannabis for over two decades. Cannabinoids are internationally recognised to reduce or alleviate symptoms and even treat certain diseases.

There remains a lack of awareness and understanding of cannabis particularly in western cultures, however it has been used for medicinal purposes by many other cultures for thousands of years. Its use became prohibited in 1937 so to reintroduce the safe use and access to this medicinal plant, it is important that we continue to support research into its use including clinical trials; and to educate medical practitioners, patients and consumers about the therapeutic benefits of the cannabis plant.

The potential range of products that can be produced from cannabinoids leads us to believe there will be numerous opportunities for commercialisation.  First movers to introduce these products to the Australian market are expected to significantly benefit and Cann Global are well positioned with the near-term launch of its Canntab products.


Medicinal Cannabis Products

Cann Global entered a 50/50 joint venture partnership with Canada-listed Canntab Therapeutics Limited (Canntab) in January 2018. Canntab Therapeutics is a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications in Canada.

Cann Global has now received the import permit to bring Canntab’s suite of pharmaceutical grade hard pill formulations to Australia. Cann Global is importing six products from the range expected to be available for sale in Australia in  2021 initially through the Special Access Scheme B (SAS-B) and Authorised prescriber schemes.

Canntab products will also be made available to Applied Cannabis Research (ACR) to support the Cannabinoid Medicinal Observational Study (CMOS), the largest study of its kind undertaken in Australia.  CMOS will collect data from 20,000 patients nationwide to assess the safety and efficacy of medicinal cannabis products.

Medicinal Cannabis Research

Cannabis as a Potential Therapy for Multiple Sclerosis

Cann Global has entered into a sponsored research agreement with the Technion Research and Development Foundation Ltd (Technion) led by Professor Dedi Meri from the faculty of biology.

Our goal is to identify the effects of different cannabinoids and terpenes both individually and in combination on the function of immune cells, specifically on MS-derived autoimmune and regulatory cells in vitro. We intend to evaluate the immunomodulatory properties of specific cannabinoid extracts in in vivo rodent models of MS. This will enable us the ability to detect the most effective Cannabis extract(s) and cannabinoid profiles for regulating immunopathology in MS. Cann Global is developing protocols to soon commence randomised controlled trials on Australian patients.